**A novel Phyto formulation of Bacopa phospholipid complex spectral characterization and its pharmacokinetic studies**

**T. Madhavi1, K. Kusuma1, K. Sai Manogna1, B. Deva Prasad Raju2 and N. John Sushma1,\***

***1Department of Biotechnology, Sri Padmavati Mahila Visvavidyalayam, Tirupati – 517 502***

***2Department of Physics, Sri Venkateswara University, Tirupati – 517 502***

**Corresponding author:**

Prof. N. John Sushma

Professor

Department of Biotechnology

Sri Padmavati Mahila Visvavidyalayam (Women’s University)

Tirupati – 517 502,

Andhra Pradesh,

INDIA.

*Email* : [**johnsushma@gmail.com**](mailto:johnsushma@gmail.com)

Phone : +91-9542423303

**Abstract**

A novel phyto formulation, *Bacopa* phospholipid complex (BPC) was developed, its physicochemical properties and pharmacokinetic studies were evaluated in albino rats for its improved absorption and bioavailability, and compared with *Bacopa monniera* extract (*Bm*). The current study comprises the analytical parameters such as Phase contrast microscope, SEM, TEM, AFM, FTIR, XRD, Zeta potential and TGA/DTA were used to characterize the BPC. The structure of BPC was assed as spherical under microscopic view, asymmetrical and spheroid shape vesicles under SEM, in which *Bm* was embedded in the phospholipids. TEM images depict the formation of vesicular structure and strong physical entanglement of *Bm* and phospholipids, 2D & 3D surface morphology was observed in AFM. The FT-IR spectroscopy showed the characteristic peaks of functional groups of bioactive compounds that are present in BPC. Likewise, the crystalline nature of the *Bm* and BPC was demonstrated by XRD. The particle size of the BPC was evaluated as 350.6 nm on average and zeta potential value was -36.6 mV which endorse the stability of the complexation. Further, the thermal behavior of BPC was observed through TGA/DTA. In pharmacokinetic studies, higher serum concentrations of Bacoside **-**A3 (1.08 mg/mL), Bacopaside II (5.59 µg/mL), Jujubogenin (1.8 µg/mL), Bacopasaponin **-**C (1.18 µg/mL) and Bacopaside **–** I (2.4 µg/mL) were observed and compared with *Bm*. Hence, BPC has shown enhancement of absorption and bioavailability compared to *Bm* in rats. Therefore, the *Bacopa* phospholipid complex (BPC) is beneficial as a functionalized material for analytical purposes as well pharmaceutical ingredient.

**KEYWORDS:** *Bacopa* phospholipid complex (BPC); TEM; AFM; Pharmacokinetic studies.

**Introduction**

Besides the traditional use of herbal medicines, extensive research has been conducted to establish a pharmacological basis of action and drug delivery, aiming to provide scientific insights [1]. Notably, the bioavailability of phytoconstituents is often limited, leading to reduced efficacy and inadequate systemic delivery [2]. Additionally, water solubility plays a pivotal role in modulating the delivery characteristics of phytoconstituents, thereby affecting crucial pharmacokinetic properties such as absorption, diffusion, release rate, and overall drug delivery [3].Nevertheless,currently various approaches such as solid dispersions [4], pro-drug strategies [5], cyclodextrin complexation, and phospholipid complexation [6,7], solvent deposition [8] have been suggested to overcome this problem. Among these, the phospholipid complexation was an advanced and prominent replica for enhanced bioavailability, drug-loading capacity, and controlled drug release with significant clinical advantages [9-11]. Due to the amphiphilic nature of the phospholipids, choline binds to the phytoconstituents which are further surrounded by the hydrophobic part of the phospholipid *i.e.* phosphatidyl portion. Thus, the phospholipids are appropriate to practice as excipients for hydrophobic drugs/phytoconstituents [12]. The phospholipid complex not only enhances the bioavailability, but also influences the aqueous solubility, phytoconstituents/drug uptake and release, and provides protection against drug destruction in the oral cavity [13].*Bacopa monniera* (*Bm*), is an ayurvedic medicine used to treat various ailments including insomnia, epilepsy, and anxiety, is endorsed as a mild sedative and memory booster [14]. Moreover, various studies have shown that Brahmi (common name of *Bm*) plays a substantial role in the prevention/treatment of neurological diseases and enrichment of cognitive conditions [15]. Further, a recent study disclosed that the ethanolic extract of *Bm* contains five dammarane saponin glycosides *viz*. Bacoside A3, Bacopaside**-**II, 3-*O*-[α-L-arabinofuranosyl (1→2)-{β-D-glucopyranosyl-(1→3)}-α-L-arabinopyranosyl] jujubogenin, Bacopasaponin C and Bacopaside I [14].

Equally, the evaluation of novel bioactive constituents such as liposomes, polymeric nanoparticles, phytosomes have significance in the development of Phyto-formulations. Nevertheless, the Phytoconstituents complexed with phospholipids maintained enhanced solubility, stability, bioavailability, absorption, and permeation of phytoconstituents through safeguard(s) destruction of physical and chemical assets [16]. Furthermost oral-drugs (lipophobic) cannot pass across lipid-rich biological membranes due to their polar nature and large molecular size. Therefore, attempts have been made to develop phytosome delivery system to overcome this problem and enhance bioavailability [17].To this aspect, phospholipids are mainly employed to make phytosomes by considering their biocompatible together phyto active constituents. Likewise, earlier studies on phytosome technology have demonstrated that the number of plant extracts such as grape seeds,maidenhair tree, crataegus, green tea, milk thistle, and ginseng heightened the therapeutic efficacy and oral absorption [18]. Another study [19] concluded that the silybin–phospholipids complex has antioxidant potential and, more protective potential of the liver than its pure molecule. The curcumin phospholipid complex has also been evaluated in terms of hepatoprotection against carbon tetrachloride toxicity, which has shown a marked increase in bioavailability, absorption, and therapeutic efficacy in mice through pharmacokinetic studies [2]. Therefore, the present investigation aims to formulate the bacopa phospholipid complex (BPC) and to evaluate its physicochemical and pharmacokinetic properties.

***Methodology***

***Preparation of Bacopa monniera (Bm) extract***

*Bacopa monneria (Bm)* plants were collected from Thummala Gunta fields, Tirumala hill ranges, Tirupati, Andhra Pradesh, India and was identification and authentication of *Bm* has done by Dr. K. Madhava Chetty, Department of Botany, Sri Venkatewara University, Tirupati, Andhra Pradesh, India (Voucher No.1213). The plant material underwent a series of steps for preparation: it was dried, ground into a powder, and extracted using ethanol solvents with a Soxhlet apparatus as mentioned in [20].

***Formulation of Bacopa-phospholipid complex (BPC)***

*In the formulation of the Bacopa-phospholipid complex (BPC), we followed a methodology similar to that described by [21].*

**Characterization techniques**

***Microscopic view of the complex***

The morphological observation of BPC was done by a Phase contrast microscope. The suspension of BPC was made with water and a drop of BPC was placed on a micro-slide, covered with a cover slip, and then observed under the microscope.

***Scanning Electron Microscopy (SEM)***

The morphology of BPC was observed by using a scanning electron microscope (Zeiss EVO 50).

***Transmission electron microscopy (TEM)***

BPC was analyzed through an electron microscope (Hitachi H-7500 operated at an accelerating voltage at 200KV) by suspending in phosphate buffer (pH7.4) through sonication with 10 min.

***Atomic Force Microscopy (AFM)***

2D and 3D topography of BPC was measured through atomic force microscopy (AFM-Solver Next, NT-MDT, Russia).

***UV and FT-IR Spectroscopy***

The optical properties of BPC were measured by UV–Vis spectrophotometer (Genesys 10S UV–Vis spectrophotometer) and FTIR spectrophotometer (Bruker Alfa –T model 109974) to detect the characteristic peaks/ functional groups of the sample.

***Measurement of particle size***

100 μL of BPC was diluted with PBS (pH 7.4) and the diameter of the BPC vesicle was determined by a particle size analyzer (Horibo scientific nanopartica SZ100 Z).

***Measurement of Zeta potential***

Zeta potential (ZP) was used to discern the physical stability of the sample. Greater stability of the particles is attained through superior electrostatic repulsion between the particles. The Zeta potential of the BPC suspension was measured by using a Zeta size analyzer (Horibo scientific nanopartica SZ100 Z). 1 mL of the BPC was diluted to 10 mL with double distilled water, in this 5mL sample was transferred to a cuvette and the zeta potential was measured.

***X-ray Diffraction Analysis***

X-ray diffraction patterns of BPC and *Bm* were measured by using Bruker Axs- D8 Discover Powder X-ray diffractometer (Germany). The X-ray generator was maintained at 40 KV and 40 mA of tube current, Ka lines of copper is used as the radiation source. The scanning angle ranged from 1 to 60oC of 2θ in step scan mode (step width 0.4 /min).

***Thermal gravimetric analysis (TGA)/Differential thermal analysis (DTA)***

Detection and measurements like thermal effects, loss of solvent, and decomposition of BPC and *Bm* were measured by using TA-Instruments, SDT Q600.

***Entrapment efficiency***

BPC was formulated with different molar ratios batches 1-5with 0.5, 1.0, 1.5, and 2.0 M egg lecithin, respectively. *Bm* entrapment efficiency in BPCwas analyzed by centrifugation. From all batches, 100 mg of BPC was dispersed in 50 ml of distilled water and centrifuged at 20,000 rpm in a refrigerated centrifuge. The collected clear solution was filtered to measure the particle-free *Bm* concentration after suitable dilution with fresh phosphate buffer saline. The absorbance was read at 266 nm in a UV spectrophotometer to calculate the entrapment efficiency using the following formula.

**Entrapment efficiency**  = Weight of the *Bm* incorporated in the BPC X 100

Weight of the *Bm* initially taken

***Dissolution study (in vitro release)***

The dialysis bag diffusion techniquewas used to measure the *in vitro* release of BPC [22]. The study was performed in a media of phosphate buffer (pH 5.5) and methanol (75:25). 2 mg of BPC was suspended in distilled water, transferred to a cellulose dialysis bag, and sealed on both sides. The dialysis bag contained BPC and media were shifted to the receptor unit and the temperature of the receptor unit was maintained at 32 ± 2°C in a rotatory water bath shaker (100 rpm). To avoid evaporation of the dissolution medium, the receptor unit was covered with aluminum foil. Total release time is 0 to 12 h with 1 h interval. For every 1 h, 2 mL of sample was collected from the receptor unit and replaced with the same amount of phosphate buffer and methanol media. After completion of time intervals (0-12 h), the collected samples were read in a spectrophotometer at 200 to 400 nm.

**BPC released (%)** = Amount of BPC released X 100

Initial amount BPC

***In vivo Pharmacokinetics Studies***

Rats were randomized into two groups, each contain six rats age of 12 months. Ethical committee approved this study by CPCSEA/IAEC (1677/PO/Re/S/2012/CPCSEA/IAEC-37dt.6/6/16). The experimental animals received human care based on the Guidelines of the National Institutes of Health and Animal Care. Animals were procured from the Sri Venkateswara Traders, Bengaluru, Karnataka. Animals were kept for fasting for overnight before serum collection and allowed to drink water *ad libitum.* Both *Bm* and BPC 40 mg/kg b.w suspension was made with distilled water and Tween-20 (1% v/v) administered orally. After that, blood samples were collected from retro-orbital plexus into tubes with heparin at time intervals of 0, 1, 2, 3, 4, 5 h.

***Preparation of Serum Samples***

The collected blood samples were centrifuged at 3000 rpm for 10 min and serum was isolated separately. 10 mL of aliquots were transferred to 10 mL volumetric flask and final volume was made with methanol, after that turbid solution was centrifuged at 5000 rpm for 10 min in 15 mL volumetric centrifuge tubes. After centrifugation supernatant was collected and measured to find the bacosides content through HPLC.

***HPLC Analysis***

The bacoside concentration in serum was measured by HPLC (Shimadzu LC-2010, Japan). The stationary phase contains Hypersil ODS, C-18 250mm X 4.6 mm, 5 mM was kept at 25oC. Mobile phase consists of 0.2% phosphoric acid: acetonitrile: methanol (60:30:10) pH 3 adjusted with NaOH. The flow rate was 1.5 mL/min and effluent was monitored at 205 nm and peaks observed were noted down [23].

***Statistical analysis***

Data expressed as mean ± SEM and difference between groups were considered significant at p<0.05 using one-way ANOVA (Analysis of Variance).

**Results and Discussion**

***Morphological features of BPC by phase contrast microscope***

The surface morphology of BPC was studied by a phase contrast microscope. The microscopic view of BPC indicated the presence of vesicles that are spherical in shape. In these vesicles, phospholipids and *Bm* were intercalated in the lipid layer **Fig 1(a).**

***Scanning Electron Microscopy (SEM)***

The SEM **Fig. 1(b)** showed that the *Bm* was associated with phospholipid, in the formation of a complex with irregular vesicles. This may be due to the hydrogen bonding between the *Bm* constituents and phospholipids [24]. This is in consonance with the validation that a pure molecule ofcurcumin hydrogenated soy phosphatidylcholine lipid layer in the curcumin phospholipid complex. The morphology of the curcumin phospholipid complex is spherical and self-closed structure, suggesting that phospholipids carry the amphipathic nature of water dispersion associated with phospholipids [25]. In the same mode, *Bm* is also equally scattered in the phospholipids and forms asymmetrical spheroid shape vesicles during the complexation [18].

***Transmission electron microscopy (TEM)***

Further, the TEM imageof BPC reveals that many spherical to spheroid shape vesicles are arranged as a very thin layer surrounding the uniform particles, which validates the *Bm*-enriched phospholipid complex as presented in **Fig 1(c)**. The vesicles have strong physical entanglement of *Bm* and phospholipids, and the polar bodies of phospholipids combined with *Bm* that gives strong aggregation for BPC.

***Atomic Force Microscopy (AFM)***

AFM measurements show the BPC surface topography, which is indifferent spherical or ellipsoidal **Fig. 1(d)** heights in a heap. These piles were elevated suddenly from the level of the surface and accomplished renowned heights compared to the adjacent side heaps. The average size of the BPC was 10µm with spectral RMS in 6.21 nm. This complexation of *Bm* and phospholipids didn’t change the original amphipathic nature and morphology. *Bm* and BPC absorption peaks were observed at 294 nm and are consistent with the previous report [26].

***UV and FT-IR Spectroscopic analysis***

The UV spectra of *Bm* and BPC are shown in **Fig. 2,** with absorption peaks observed at 296 nm. FT-IR spectrum **Fig. 3(a&b)** showed the presence of functional groups both in *Bm* and BPC. Likewise, the major absorption peaks of *Bm* showed at 3386 cm-1 assigned to primary, secondary amines N-H stretch, 2927 cm-1 integrated for alkane C-H stretch, 2091 cm-1 assigned to alkynes (terminal), and 1703 cm-1 correspondstoC=O stretch of carbonyl derivatives. While the BPC showed prominent peaks at 3292 cm-1(N-H stretch) signifies primary, secondary amines, 2925 cm-1(C-H stretch) corresponds to alkane, and 1744 & 1651 cm-1(C=O stretch)corresponds to esters/acid and aldehyde functionalities, and 1235 cm-1 represents C-N/C-O/C-C deformations of aliphatic amines/ethers. Further, the FT-IR spectra of BPC showed broadening, sharp and articulate peaks of various bio-active molecules. The FT-IR broad bands demonstrated that the interaction between *Bm* and phospholipids has a strong steric hydrogen bonding (OH) which accommodates the formulation of BPC. As well, the shifting of bands from higher frequency to lower frequency indicates the new bonding(s) between phospholipids and *Bm* constituents. Moreover, the BPC showed additional bands that signify the choline groups N-(CH3)3 presence in phospholipids. [17].

***Particle size and Zeta potential***

Zeta potential was used to estimate the firmness of formulations and the present study also includes the particle size and zeta potential measurements of BPC. It was observed that BPC has an average particle size of 552.5 nm, and the zeta potential value was -36.6 mV, indicating the stability of the formulation as graphically exemplified in **Fig. 4**.

***X-ray Diffraction (XRD) Analysis***

The XRD profile in **Fig. 5** shows intense crystalline peaks of *Bm* extract that indicate higher crystallinity. However, in the case of BPC, peaks are relatively less intense than *Bm* due to the crystalline diffraction of phospholipids during BPC formation [27]. As well, the previous reports of the phospholipid complex of diclofenac and naringenin, puerarin, insulin, and salmon calcitonin also supported the current study [28].

***Thermal analysis (TGA/DTA)***

Thermogravimetry (TG) and differential thermal analysis (DTA) are the most common analyzing thermal tools used for the assessment of quality of the plant drugs [29]. TG curve of *Bm* in **Fig.** **6** showed the weight loss (50.64%) that gradually decreased from 131.21°C to 490.84°C due to the degradation of bounded water molecules. Similarly, the BPC of the TG curve shows a weight loss of 62.77% from 204.98°C to 411.79°C. Because of the abundance of hydrogen molecules in BPC more weight loss (62.77%) compared to the *Bm*. Furthermore, differential thermal analysis (DTA) is a suitable, authentic, and fast method to find the interaction between drugs and excipients. Since interactions are defined by the expulsion of endothermic peaks, the abrupt raise of new peaks, and a number of changes like temperature, and enthalpy also affect the peak [2]. The thermogram (DTA) in **Fig.7** demonstrates that the endothermal peak at 76.88°C and exothermal peak at 194.67°C for *Bm*. Though, for the BPC, the endothermal peak was observed at 150°C and the exothermal peak at 200.96 °C, together with additional tiny endothermal peaks at 240°C and 270°C. This may be due to the hot motion of the phospholipid polar head groups and the phase transition(s). Accordingly, it was apparent that the *Bm* peaks were melted away in the thermogram of BPC. Further, the phase transition temperature of BPC was a higher temperature than *Bm*, which ensures the complexation of BPC [30-32], and the fact that both *Bm*and phospholipids are bound by hydrogen bonds or Van der Waals force.

***Entrapment Efficiency***

The entrapment efficiency of *Bm* was calculated with different formulations as shown in the various batches listed below in **Table 1**. The maximum entrapment efficiency of 86.04 % was observed in B2 and the minimum of 39.80% was in B4 as depicted in **Fig. 7**. Consequently, batch B2 was used for the physicochemical and pharmacokinetic analysis.

**Table 1**: An assessment of Entrapment efficiency of various batches of *Bm* used in the current study

|  |  |  |
| --- | --- | --- |
| **S.No** | **Batch no.** | **Entrapment efficiency (w/w %) ± SD** |
| I | B1 | 46.2±0.4 |
| II | B2 | 86.04±0.7 |
| III | B3 | 61.02±0.9 |
| IV | B4 | 39.8±0.29 |
| V | B5 | 52.46±0.6 |

***Dissolution study (In vitro release)***

The *in vitro* release study was performed with the dialysis membrane diffusion technique for 12 h and the results were shown in **Fig. 8**. Throughout the process, the BPC was released by diffusion mechanism from the dialysis membrane. The *Bm* has OH ions, which can form hydrogen bonds between *Bm* and phospholipid molecules, and thus BPC was easily adsorbed. BPC was released within 2h, which may be due to the penetration of buffer into the BPC molecules by pores dissolving from the surface under favorable conditions like pH of the buffer, temperature, lipid concentration, and high solubility. The instantaneous *in vitro* release of BPC within 2 h may be due to well-constructed interactions with phospholipids and *Bm* containing phyto-constituents.

***In vivo studies***

A postulate that the pharmacokinetic studies of oral administration of BPC in rat serum indicates the presence of Bacoside A3, Bacopaside II, Jujubogenin, Bacopasaponin C and Bacopaside I. BPC was found to be rapidly absorbed in 1-2 h without presenting any absorption lag time with quality of bacosides and peak concentrations of Bacoside **-**A3 (1.08 µg/mL), Bacopaside II (5.59 µg/mL), Jujubogenin (1.8 µg/mL), Bacopasaponin **-**C (1.18 µg/mL) and Bacopaside **–** I (2.4 µg/mL). The *Bm* peak concentration of Bacoside **-**A3(0.17 µg/mL), Bacopaside II (1.86 µg/mL), Jujubogenin (0.15 µg/mL), and Bacopasaponin **-**C (1.18 µg/mL) and Bacopaside I (2.4 µg/mL) showed less bioavailability within 2h as labeled in **Fig:9(a-e)** that presenting more than 3h absorption time. Thus, the pharmacokinetic studies reveal the Cmax and Tmax of five components *i.e.* Bacoside A3, Bacopaside II, Jujubogenin, Bacopasaponin C, and Bacopaside I. The complexation of *Bm* with phospholipids shows physicochemical entanglement to improve its effective half-life in bioavailability and absorption compared with uncomplexed *Bm*, suggesting that the formulations can improve absorption and bioavailability in serum, tissue, and metabolism of *Bm*. Further, classified studies have shown that oral administration of lipid-based formulations of phyto constituents/drugs exhibits greater therapeutic potential than the original phyto constituents/drugs. In the same manner, the results of the current study are also in good agreement with the literature [17] because the serum peak concentration increased after the formulation of BPC compared to the *Bm*, which exhibited good bioavailability and absorption.

**Conclusions**

BPC is formulated with *Bm* extract and phospholipids to enhance the absorption and bioactive principle with better therapeutic strategies. The morphology and structural studies such as the size and shape of the BPC were determined through various analytical parameters like phase contrast microscope, SEM, TEM, and AFM. Further, the BPC was optimized and characterized by UV–Vis spectroscopy by integrating the absorption peak observed at 296 nm. FT-IR investigations clearly depicted the presence of functional groups in the *Bm* and BPC. In addition, the validation of complex formulation was achieved by witnessing the shifting of *Bm* higher wave number to lower wave number in BPC due to the merging of *Bm* and phospholipids. Moreover, the Zeta potential value -36.6 mV demonstrated higher stability, and the XRD studies indicated the amorphous nature of BPC. Likewise, thermal studies also show the stability of BPC at 400oC. Moreover, the *in vitro* release studies indicate that novel BPC could be a better way for the immediate release of *Bm*. In pharmacokinetic studies, the serum peak concentration was increased after the formulation of BPC compared to the *Bm.* Therefore, from the perceived results that the BPC has been found as a potential for bacoside delivery and has been found to be a novel technology for drug delivery and disease therapy. Thus, the current study endorsed the complexation of plant extracts like BPC for pharmacological therapies as a substitute for its individuals after measuring its toxic parameters.

**Acknowledgments**

Ms T. Madhavi gratefully acknowledges University Grants Commission (UGC), New Delhi, India for providing financial assistance in the form of Rajiv Gandhi National Fellowship (RGNF)F1-17.1/2015-16/RGNF-2015-17-SC–AND-7719/ (SAIII/Website) to carry out this research work.

**References**

1. SR Khafaga, D., & Ewies, E. F. (2023). Drug Delivery Systems Designed to Maximize the Therapeutic Efficacy of Herbal Medication: A Review Article. Egyptian Journal of Chemistry..
2. Hirano-Kusuda, M., Setoguchi, S., Koga, M., Goto, S., Yamada, A., Watase, D., ... & Takata, J. (2023). Cationic Ester Prodrugs of Curcumin with N, N-dimethyl Amino Acid Promoieties Improved Poor Water Solubility and Intestinal Absorption. Pharmaceutical Research, 1-12.. 2007; 330:155–163.
3. Pourmadadi, M., Eshaghi, M. M., Ostovar, S., Mohammadi, Z., Sharma, R. K., Paiva-Santos, A. C., ... & Pandey, S. (2023). Innovative nanomaterials for cancer diagnosis, imaging, and therapy: Drug deliveryapplications. Journal of Drug Delivery Science and Technology, 104357..
4. [Zhang Z,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Zhang%20Z%5BAuthor%5D&cauthor=true&cauthor_uid=24456672)   [Chen](https://www.ncbi.nlm.nih.gov/pubmed/?term=Chen%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=24456672) Y, [Deng J,](https://www.ncbi.nlm.nih.gov/pubmed/?term=Deng%20J%5BAuthor%5D&cauthor=true&cauthor_uid=24456672) et al. Solid dispersion of berberine-phospholipid complex/TPGS 1000/SiO₂: preparation, characterization and in vivo studies. [Int J Pharm.](https://www.ncbi.nlm.nih.gov/pubmed/24456672) 2014; 465: 306-316.
5. [Stella](http://www.sciencedirect.com/science/article/pii/S0169409X07000865?via%3Dihub#!) VJ,  [Nti-Addae](http://www.sciencedirect.com/science/article/pii/S0169409X07000865?via%3Dihub#!) KW. Pro drug strategies to overcome poor water solubility, Adv Drug Deliv Rev. 2007; 59: 677-694.
6. Khan J, Alexander A, Ajazuddin Saraf S, et al. Recent advances and future prospects of phyto-phospholipid complexation technique for improving pharmacokinetic profile of plant actives. J Control Release. 2013;168: 50–60.
7. Ahmad H, Arya A, Agrawal S. Phospholipid complexation of NMITLI118RT+: way to a prudent therapeutic approach for beneficial outcomes in ischemic stroke in rats. Drug Deliv. 2016; 23: 3606-3618.
8. Semalty A, Singh Y, Semalty TM. Preparation and characterization of cyclodextrin inclusion

complex of naringenin and critical comparison with phospholipid complexation for improving solubility and dissolution. J Therm Anal Calorim. 2014; 115:2471–2478.

1. Ma Y, Li H, Guan S. Characteristics and evaluation of an injectable clarithromycin lipid-based complex in vitro and in vivo, Drug Deliv. 2013; 20: 349–355.
2. Xie Y, Luo H, Duan J, et al. Phytic acid enhances the oral absorption of isorhamnetin, quercetin, and kaempferol in total flavones of Hippophae rhamnoides L. Fitoterapia*.* 2014; 93:216-225.
3. Khatik R, Dwivedi P, Shukla A. Development, characterization and toxicological evaluations of phospholipids complexes of curcumin for effective drug delivery in cancer chemotherapy. Drug Deliv. 2016; 23:1067–78.
4. Singh D, Rawat MSM, Semalty A, et al. Emodin–phospholipid complex. A potential of herbal drug in the novel drug delivery system. J Therm Anal Calorim. 2012; 108:289–298.
5. Zhou X, Zhao Y, Chen S. Self-assembly of pH-responsive microspheres for intestinal delivery of diverse lipophilic therapeutics. Biomacro molecules. 2016; 17:2540–2554.
6. Mathur D, Kritika G, Veena K, et al. The Molecular Links of Re-Emerging Therapy: A Review of Evidence of Brahmi (Bacopa monniera). Frontiers in Pharmac. 2016; 7:1-15.
7. Chowdhari D, Parmar K, Kakkar D, et al. Anti stress effects of bacosides of *B*acopa monnieri: modulation of hsp70 expression, superoxide dismutase and cytochrome p450 activity in rat brain. Phytother Res. 2002; 16:639–645.
8. Ajazuddin S. Applications of novel drug delivery system for herbal formulations. Fitoterapia. 2010; 81(7): 680-89.
9. Habbu P, Smita M, Ramesh K, et al. Preparation and evaluation of Bacopa phospholipid complex for antiamnesic activity in rodents. Drug Inv today. 2013; 5:13-21.
10. Hüsch J, Bohnet J, Fricker G, et al. Enhanced absorption of boswellic acids by a lecithin delivery form (Phytosome®) of Boswellia extract. Fitoterapia. 2013;84:89–98
11. Yanyu X, Yunmei S, Zhipeng C, et al. The preparation of silybin–phospholipid complex and the study on its pharmacokinetics in rats. Int J Pharm. 2006; 307: 77–82.
12. Raaman N. Phytochemical Techniques. New India Publishing Agency, New Delhi, India; 2006.
13. Yue PF, Yuan HL, Ming Y et al. Preparation, characterization and pharmacokinetics in vivo of oxymatrine–phospholipid complex. Drug Dev Ind Pharm 2009;1:99–102 .
14. [Yang](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yang%20S%5BAuthor%5D&cauthor=true&cauthor_uid=10350020)  S,   [Zhu](https://www.ncbi.nlm.nih.gov/pubmed/?term=Zhu%20J%5BAuthor%5D&cauthor=true&cauthor_uid=10350020)  J, [Lu](https://www.ncbi.nlm.nih.gov/pubmed/?term=Lu%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=10350020)  Y,  et al. Body distribution of camptothecin solid lipid nanoparticles after oral administration, [Pharm Res.](https://www.ncbi.nlm.nih.gov/pubmed/10350020) 1999;16: 751-57.
15. Phrompittayarat W, Putlun W, Tanaka H, et al. Comparison of various extraction methods of Bacopa monnieri. Naresuan Univ J. 2007; 15:29-34.
16. Semalty A, Semalty M, Riwat MSM, et al. Supramolecular phospholipids-polyphenolics interaction: the PHYTOSOME® strategy to improve the bioavailability of phytochemicals. Fitoterapia. 2010; 81: 306-14.
17. Zhang J, Tang Q, Xu X, et al. Development and evaluation of a novel phytosome-loaded chitosan microsphere system for curcumin delivery. Int J Pharm. 2013;448: 168-174.
18. Gutiérrez JG, Isidoro RP, Pérez-Camacho M I, et al. The calorimetric properties of liposomes determine the morphologyof dried droplets. Colloids and Surfaces B: Bioint. 2017; 155: 215–222.
19. Semalty A, Semalty M, Singh D, et al. Development of physicochemical evaluation of pharmacosomes of diclofinac. Acta pharma. 2009b; 59: 335-344.
20. Sang YH, Park TG. Biodegradable nanoparticles containing protein fatty acid complex for oral delivery of salmon calcitonin. J Pharma Sci. 2003; 93: 488-495.
21. Cuinica LG, Macedo OR. Thermoanalytical characterization of plant drug and extract of Urticadioica L. and kinetic parameters analysis. J Therm Anal Calorim. 2018; 133:591–602.
22. Hwang SB, Shen TY. Membrane effects of anti-inflammatory agents Interaction of nonsteroidal anti-inflammatory drugs with liposome and pur ple membranes. J Med Chem. 1981; 24: 1202–1212.
23. Venema FR, Weringa, WD. The interactions of phospholipid vesicles with some anti-inflammatory agents. J Colloid Interface Sci. 1988; 125:484–500.
24. Lasonder E, Weringa WD. An NMR and DSC study of the interaction of phospholipids vesicles with some anti-inflammatory agents. J Colloid Interface Sci. 1990; 139: 469–478.

**Figures**















